top of page

​ News

We would like to inform you that the following officers were elected at our company's third annual (2023FY) general shareholder meeting and assumed their positions as follows. Along with Kazuto Takesako, Masanobu Kimura was nominated and approved as representative director to strengthen the management as the board member effective immediately.


From now on, all of our executives are determined to work hard to develop new cancer treatments. We appreciate your continued support.


Representative Director and President Kazuto Takesako (CEO) (remaining)

Representative Director and Vice President (COO) Masanobu Kimura (newly appointed)

Director (Outside) Kei Fujioka (Remaining, Representative Director of Takt Pharma Co., Ltd.)

Auditor Takashi Mitsuguchi (newly appointed, DBJ Capital)

Newly appointed Masanobu Kimura was born in 1963 and has consistently engaged in research and development in the cancer field, particularly clinical development as follows:

2001-2007 Daiichi Pharmaceutical Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)

2007-2010 Immuno Frontier Co., Ltd.

2010 Icon Japan Co., Ltd.

2011-2013 PAREXEL International Co., Ltd.

2013-2024 Takara Bio Co., Ltd.

April 2015: Appointed Deputy General Manager of Gene Medical Business Division and General Manager of Project Promotion Department at the company

June 2016 Appointed as executive officer of the company

June 2017 Appointed as Director and Managing Executive Officer of the company

June 2023 Managing Executive Officer of the company

Director Kiyoshi Inoguchi and auditor Yoshiyuki Wakahara have both retired. We would like to express our deepest gratitude for their work. Furthermore, Kiyoshi Inoguchi will continue supporting the management of the company as the General Manager of the Partnership Promotion Department.

January 13, 2024

T Celll Nouveau Inc.

Notice of Patent License Agreement for a

Novel CAR T-Cell Therapy Targeting GD2 Antigen

T Cell Nouveau Inc. (Headquartered in Chuo-ku, Tokyo and represented by Chairman and Representative Director, Kazuto Takesako, hereinafter referred to as the “Company”) has concluded a License Agreement (hereinafter, the 'License Agreement') with Mie University (National University Corporation, headquartered in Tsu, Mie and represented by President Masaaki Ito, hereinafter "Mie University") for the patents mentioned above (hereinafter referred to as the "License Agreement").

CAR-T cell therapy has shown groundbreaking efficacy in the treatment of leukemia and malignant lymphoma. This immunotherapy was pioneered by Kymria® with first Japan domestic approval in 2019. However, achieving similar results for solid tumors requires further advancement. To address this challenge, The Company has collaborated with the Mie University Graduate School of Medicine, Department of Personalized Cancer Immunotherapy to jointly develop T-cell therapy. Furthermore we have concluded a license agreement concerning CAR-T cell therapy targeting GD2 glycolipid.  This step aims to expedite clinical application of T-cell therapy for solid tumors and advance regenerative medicine.


About GD2:

GD2 is a glycolipid predominantly expressed on the surface of nerve cells, confirmed to be excessively expressed in various cancers, including neuroblastoma, a type of pediatric cancer, as well as tripple negative breast cancer and melanoma.

bottom of page